[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @OscarTahuahua Oscar Tahuahua Oscar Tahuahua posts on X about the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1251032080881983489/interactions)  - X Week XXXXXX -XX% - X Month XXXXXX +522% - X Months XXXXXXX +3,443% - X Year XXXXXXX +21,340% ### Mentions: X [#](/creator/twitter::1251032080881983489/posts_active)  - X Week XX +100% - X Month XX +108% - X Months XX +643% - X Year XX +867% ### Followers: XXXXX [#](/creator/twitter::1251032080881983489/followers)  - X Week XXXXX +2.90% - X Month XXXXX +12% - X Months XXXXX +82% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1251032080881983489/influencer_rank)  ### Social Influence [#](/creator/twitter::1251032080881983489/influence) --- **Social category influence** [currencies](/list/currencies) ### Top Social Posts [#](/creator/twitter::1251032080881983489/posts) --- Top posts by engagements in the last XX hours "First study to investigate the mechanisms underlying recurrence after a pathologic response to neoadjuvant ipi plus nivo in stage III Melanoma Paired genomic and immune analyses show that relapse is not driven by classical immune escape mutations (B2M JAK1/2 HLA) but by a gradual loss of immune pressure 📴 The fight isn't over when the tumor disappears only when immune surveillance stays active 🕵♂ @OncoAlert" [X Link](https://x.com/OscarTahuahua/status/1976805935407308827) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-11T00:23Z 1415 followers, 3874 engagements "HARMONi-6 In 1L squamous NSCLC ivonescimab + CTx PFS vs tislelizumab + CTx (11.1 vs XXX mo; HR 0.60) with consistent benefit across PD-L1 subgroups; OS immature; global trial pending. @OncoAlert @myESMO #ESMO25" [X Link](https://x.com/OscarTahuahua/status/1979923494704959960) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-19T14:52Z 1415 followers, 3471 engagements "#ESMO25 CheckMate 8HW In MSI-H/dMMR metastatic CRC nivo + ipi PFS (NR vs XXXX mo; HR 0.69) & with OS trend (HR 0.61) vs nivolumab alone with ORR (73% vs 61%) & good safety. Confirms dual ICI as SoC in this population Absolutely impressive results 😱 @OncoAlert @myESMO #ESMO25" [X Link](https://x.com/OscarTahuahua/status/1980162720176472270) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-20T06:42Z 1415 followers, 2708 engagements "#ESMO25 Tarlatamab + 1L chemo-IO in ES-SCLC. DeLLphi-303 ORR XX% mPFS X mo 12-mo OS XX% with a Manageable 🤨 safety profile (75% G3 TRAEs mostly hematologic related to ChT) Durable activity supports phase III DeLLphi-312 highlighting the efficacytoxicity balance @OncoAlert" [X Link](https://x.com/OscarTahuahua/status/1977904241701179737) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-14T01:08Z 1414 followers, 7333 engagements "EORTC consensus on resectable stage III NSCLC XXX cases reviewed by XX experts. Resectability criteria for trials & practice. A TNM subset was resectable if XX% agreed. T1T4 (size/satellite) w/ N0N2 single were resectable; N2 multi bulky/invasive & N3 were unresectable. Only T4 invasionN0 without consensus. Most unresectable cases combined X major anatomic factors @OncoAlert" [X Link](https://x.com/OscarTahuahua/status/1978284064802054495) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-15T02:17Z 1413 followers, 11.3K engagements "#ESMO25 FLAURA2 (Osimertinib + CTx as 1L) OS by prognostic factors ✅Global OS benefit: HR XXXX (p=0.02) ✅Benefit consistent across subgroups // statistically significant only in CNS metastases (HR 0.72) Supports combination therapy as 1L for EGFR mNSCLC" [X Link](https://x.com/OscarTahuahua/status/1979017849042612728) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-17T02:53Z 1415 followers, 5287 engagements "DESTINY-Breast11. T-DXd keeps moving earlier Neoadjuvant T-DXd-THP achieved higher pCR (67% vs 56%; XX% p=0.003) & fewer G3 AEs (38% vs 56%) vs ddAC-THP in high-risk HER2+ eBC. Early trend toward EFS (HR 0.56) Whats next T-DXd is reshaping HER2+ disease turning trimodal therapy into uni/bimodal success. With this drug every trial feels like another win. @OncoAlert @myESMO #ESMO25" [X Link](https://x.com/OscarTahuahua/status/1979557833021571125) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-18T14:39Z 1412 followers, 1702 engagements "#ESMO25 NADINA In resectable stage III melanoma neoadjuvant nivo + ipi 2y EFS (77% vs XX% HR 0.40) & DMFS (83% vs XX% HR 0.43) vs adjuvant nivo. IFN PD-L1 & TMB emerged as key predictors; IFN-high TMB-high reached XXX% EFS. @OncoAlert @myESMO #ESMO25" [X Link](https://x.com/OscarTahuahua/status/1980166599702396952) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-20T06:58Z 1415 followers, 1981 engagements "We dont have a perfect biomarker in CRC to choose between mono and dual therapy. Because of the study design PFS difference isnt statistically significant but is clinically meaningful; dual therapy isnt for everyone and Id reserve monotherapy only when toxicity is a concern" [X Link](https://x.com/OscarTahuahua/status/1980889880260456847) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-22T06:52Z 1414 followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@OscarTahuahua Oscar Tahuahua
Oscar Tahuahua posts on X about the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX -XX%
- X Month XXXXXX +522%
- X Months XXXXXXX +3,443%
- X Year XXXXXXX +21,340%
Mentions: X #
- X Week XX +100%
- X Month XX +108%
- X Months XX +643%
- X Year XX +867%
Followers: XXXXX #
- X Week XXXXX +2.90%
- X Month XXXXX +12%
- X Months XXXXX +82%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence currencies
Top Social Posts #
Top posts by engagements in the last XX hours
"First study to investigate the mechanisms underlying recurrence after a pathologic response to neoadjuvant ipi plus nivo in stage III Melanoma Paired genomic and immune analyses show that relapse is not driven by classical immune escape mutations (B2M JAK1/2 HLA) but by a gradual loss of immune pressure 📴 The fight isn't over when the tumor disappears only when immune surveillance stays active 🕵♂ @OncoAlert"
X Link @OscarTahuahua 2025-10-11T00:23Z 1415 followers, 3874 engagements
"HARMONi-6 In 1L squamous NSCLC ivonescimab + CTx PFS vs tislelizumab + CTx (11.1 vs XXX mo; HR 0.60) with consistent benefit across PD-L1 subgroups; OS immature; global trial pending. @OncoAlert @myESMO #ESMO25"
X Link @OscarTahuahua 2025-10-19T14:52Z 1415 followers, 3471 engagements
"#ESMO25 CheckMate 8HW In MSI-H/dMMR metastatic CRC nivo + ipi PFS (NR vs XXXX mo; HR 0.69) & with OS trend (HR 0.61) vs nivolumab alone with ORR (73% vs 61%) & good safety. Confirms dual ICI as SoC in this population Absolutely impressive results 😱 @OncoAlert @myESMO #ESMO25"
X Link @OscarTahuahua 2025-10-20T06:42Z 1415 followers, 2708 engagements
"#ESMO25 Tarlatamab + 1L chemo-IO in ES-SCLC. DeLLphi-303 ORR XX% mPFS X mo 12-mo OS XX% with a Manageable 🤨 safety profile (75% G3 TRAEs mostly hematologic related to ChT) Durable activity supports phase III DeLLphi-312 highlighting the efficacytoxicity balance @OncoAlert"
X Link @OscarTahuahua 2025-10-14T01:08Z 1414 followers, 7333 engagements
"EORTC consensus on resectable stage III NSCLC XXX cases reviewed by XX experts. Resectability criteria for trials & practice. A TNM subset was resectable if XX% agreed. T1T4 (size/satellite) w/ N0N2 single were resectable; N2 multi bulky/invasive & N3 were unresectable. Only T4 invasionN0 without consensus. Most unresectable cases combined X major anatomic factors @OncoAlert"
X Link @OscarTahuahua 2025-10-15T02:17Z 1413 followers, 11.3K engagements
"#ESMO25 FLAURA2 (Osimertinib + CTx as 1L) OS by prognostic factors ✅Global OS benefit: HR XXXX (p=0.02) ✅Benefit consistent across subgroups // statistically significant only in CNS metastases (HR 0.72) Supports combination therapy as 1L for EGFR mNSCLC"
X Link @OscarTahuahua 2025-10-17T02:53Z 1415 followers, 5287 engagements
"DESTINY-Breast11. T-DXd keeps moving earlier Neoadjuvant T-DXd-THP achieved higher pCR (67% vs 56%; XX% p=0.003) & fewer G3 AEs (38% vs 56%) vs ddAC-THP in high-risk HER2+ eBC. Early trend toward EFS (HR 0.56) Whats next T-DXd is reshaping HER2+ disease turning trimodal therapy into uni/bimodal success. With this drug every trial feels like another win. @OncoAlert @myESMO #ESMO25"
X Link @OscarTahuahua 2025-10-18T14:39Z 1412 followers, 1702 engagements
"#ESMO25 NADINA In resectable stage III melanoma neoadjuvant nivo + ipi 2y EFS (77% vs XX% HR 0.40) & DMFS (83% vs XX% HR 0.43) vs adjuvant nivo. IFN PD-L1 & TMB emerged as key predictors; IFN-high TMB-high reached XXX% EFS. @OncoAlert @myESMO #ESMO25"
X Link @OscarTahuahua 2025-10-20T06:58Z 1415 followers, 1981 engagements
"We dont have a perfect biomarker in CRC to choose between mono and dual therapy. Because of the study design PFS difference isnt statistically significant but is clinically meaningful; dual therapy isnt for everyone and Id reserve monotherapy only when toxicity is a concern"
X Link @OscarTahuahua 2025-10-22T06:52Z 1414 followers, XX engagements